Renew Biotechnologies to Evaluate NeuroLens Technology in Multiple Sclerosis in Mayo Clinic Collaboration

Renew Biotechnologies has entered into a clinical development collaboration with Mayo Clinic to evaluate NeuroLens®, the company's cell-free DNA (cfDNA)-based approach, in multiple sclerosis (MS) and related neuroimmunologic diseases. The initiative aims to develop minimally invasive biomarkers that can offer deeper insights into active central nervous system (CNS) injury and its progression over time, with the goal of supporting more informed patient care.

The study will build upon Renew's previous research in conditions such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. It will specifically examine cfDNA cell-of-origin signatures linked to cell death within patient populations diagnosed with neuroimmunologic diseases. The research will focus on identifying injury signatures associated with neurons, astrocytes, and oligodendroglial cells, assessing their correlation with disease differentiation, phenotype, stage, severity, and progression.

Mayo Clinic will contribute clinical expertise and access to well-characterized biorepository resources to guide the research. This includes informing the design of clinically meaningful studies, identifying relevant proof points, and providing characterized samples essential for evaluating the relationship between NeuroLens signals and disease presentation and progression.

"Complex neurological diseases present clinical questions that require both strong molecular tools and deep clinical context," said Chad Pollard, Co-Founder and CEO of Renew Biotechnologies. "Working with Mayo Clinic will help us explore new applications for NeuroLens and provide insights as we seek to expand its potential to benefit patients across a broader range of neurological diseases."

While the initial focus will be on MS, the collaboration has the potential to expand to other neuroimmunologic diseases as study criteria are met. Investigators plan to analyze the links between cell-of-origin signals and disease phenotype, progression, relapse activity, treatment response, and disability over time, aiming to enhance understanding of how these molecular insights could ultimately support disease assessment and improve patient care.